In a new study, Younossi et al. poignantly depict the daunting and enormous prevalence of NAFLD and its associated clinical and economic burden in the USA and four countries in Europe. The astronomical health-care costs will increase as the prevalence of NAFLD increases. All stakeholders are called to action.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Exercise training attenuates pulmonary inflammation and mitochondrial dysfunction in a mouse model of high-fat high-carbohydrate-induced NAFLD
BMC Medicine Open Access 08 November 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Younossi, Z. M. et al. The economic and clinical burden of non-alcoholic fatty liver disease (NAFLD) in the United States and Europe. Hepatology http://dx.doi.org/10.1002/hep.28785 (2016).
Rinella, M. E. et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap. Adv. Gastroenterol. 9, 4–12 (2016).
Said, A., Gagovic, V., Malecki, K., Givens, M. L. & Nieto, F. J. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann. Hepatol. 12, 758–765 (2013).
Wong, V. W. et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 59, 536–542 (2013).
Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378.e5 (2015).
Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010).
Sun, W. et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol. Res. 46, 862–870 (2016).
Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).
Kargiotis, K. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J. Gastroenterol. 21, 7860–7868 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Abdelmalek, M. The clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol 13, 685–686 (2016). https://doi.org/10.1038/nrgastro.2016.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.178
This article is cited by
-
Exercise training attenuates pulmonary inflammation and mitochondrial dysfunction in a mouse model of high-fat high-carbohydrate-induced NAFLD
BMC Medicine (2022)
-
Paving the way: the road to be taken for proper NAFLD health care
Nature Reviews Gastroenterology & Hepatology (2022)
-
Blood and urine manganese exposure in non-alcoholic fatty liver disease and advanced liver fibrosis: an observational study
Environmental Science and Pollution Research (2022)
